DuPont delivered a strong finish to 2025, beating previous guidance with full-year adjusted EPS of $1.68 (up 16% year-over-year) and operating EBITDA growth of 6%. The company achieved 2% organic sales growth and 100 basis points of margin expansion, driven by operational discipline and productivity gains, while successfully completing the separation of its Electronics segment. Strategic highlights include a robust innovation engine that launched 125 new products, generating over $2 billion in sales with a vitality index of 30%. Looking ahead to 2026, DuPont provided confident guidance for organic sales growth of approximately 3%, adjusted EPS of $2.25 to $2.30 (representing 11% pro forma growth), and continued margin expansion of 60 to 80 basis points, underpinned by secular tailwinds in healthcare and water and a focus on commercial excellence.
| Metric | Value | Change |
|---|---|---|
| Q4 Net Sales | $1.7 Billion | ~Flat YoY |
| Q4 Organic Sales Growth | -1% | N/A |
| Q4 Operating EBITDA | $409 Million | +4% YoY |
| Q4 Op EBITDA Margin | 24.2% | +80 bps YoY |
| Q4 Adjusted EPS | $0.46 | +18% YoY |
| FY 2025 Adjusted EPS | $1.68 | +16% YoY |
| FY 2025 Organic Sales Growth | 2% | N/A |
| FY 2026 EPS Guidance | $2.25 - $2.30 | +11% Pro Forma |
| FY 2026 Organic Sales Guidance | ~3% | N/A |
| Vitality Index | ~30% | Stable |
Management emphasized a decisive pivot from portfolio restructuring to operational execution and internal growth drivers. The completion of the Electronics separation and the Aramis divestiture marks the end of a major transition era, allowing leadership to focus entirely on 'New DuPont.' This focus is manifested in the build-out of a robust business system, the expansion of Kaizen events, and the implementation of enhanced KPIs to drive commercial and operational excellence. The signal here is that the company believes its current portfolio is streamlined and aligned with secular growth markets, and future value creation will come from margin expansion and market share gains rather than M&A or spin-offs.
Innovation remains a primary growth vector, with management highlighting a 'vitality index' of roughly 30%, consistent with prior periods. The company launched 125 new products in 2025, which generated over $2 billion in sales. Crucially, management noted that the margin profile of these new products is higher than the company average, contributing approximately 145 basis points of margin lift. This indicates that R&D spending is translating directly into both top-line growth and profitability, reinforcing the investment thesis around DuPont's high-value application development in healthcare and water.
DuPont is positioning itself to benefit from secular trends in Healthcare and Water Technologies, which are expected to grow mid-single digits in 2026, outpacing the broader industrial economy. In Healthcare, growth is driven by an aging population and specific strength in cardiovascular devices and medical packaging. In Water, despite near-term softness in China due to industrial production declines, the company is investing in capacity (e.g., Gen 4 RO expansion in Edina) to capture long-term demand for industrial and municipal water treatment. This strategic alignment reduces reliance on cyclical industrial markets.
Capital allocation remains a key pillar of shareholder returns, characterized by a 'balanced model' and a shareholder-friendly stance. The company executed a $500 million Accelerated Share Repurchase (ASR) in 2025 and retains a $2 billion authorization. With the Aramis divestiture expected to close in Q1 2026 for ~$1 billion in net tax proceeds, management signaled continued deployment into M&A (specifically targeting healthcare tuck-ins) and further buybacks. The commitment to a quarterly dividend and >90% free cash flow conversion in 2026 provides visibility on returns.
Management signaled a stabilization in end markets that have been headwinds, specifically Construction and Industrial Technologies. While the overall outlook for auto builds is flat, DuPont expects to outperform with EV growth. In construction, the company expects a move from 'down mid-single digits' to 'flattish' demand in 2026, driven by non-residential and repair and remodel. The observation of 'improving order trends' in Industrial Technologies suggests the worst of the industrial downcycle may be in the rearview mirror, supporting the guidance for low single-digit growth in the Diversified Industrials segment.
While the overall tone was positive, management acknowledged persistent macro headwinds that limit the upside potential for the Diversified Industrials segment. Overall automotive demand is projected to be flat in 2026 with specific weakness in the US and Europe. Furthermore, while construction is stabilizing, it is not expected to return to robust growth, merely 'flattish' performance. This creates a dynamic where the company must rely heavily on its Healthcare and Water segments to offset structural weakness in the industrial side of the portfolio.
The Water business faces a specific near-term demand challenge in China, a critical growth market. Management admitted that water sales in China are starting the year in the 'low single digits' due to reduced industrial production in the region. While they expect a ramp in the second half of 2026, any prolonged slowdown in Chinese industrial activity could pressure the segment's ability to meet its mid-single-digit growth target for the full year.
Pricing power appears to be moderating compared to the inflationary period of 2022-2023. Management stated that the 3% organic growth guidance for 2026 is 'predominantly related to volume.' They explicitly noted that they expect to 'give back a little bit on the shelter side' as previous price increases unwind. This shift from price-driven growth to volume-driven growth increases the importance of execution on volume targets and exposes the company to volume risk if demand softens.
The guidance for 2026 implies a significant step-up in earnings (35% reported growth), yet some of the operational initiatives cited as drivers, such as the '80/20' portfolio optimization and the broader business system implementation, are still in early stages. Management noted that the benefits of 80/20 are 'to come.' This creates an execution risk where the ambitious margin expansion targets (60-80 bps) rely heavily on the successful rollout of these operational frameworks rather than just easy cyclical recovery.
Overall: Management exhibited a high level of confidence and discipline throughout the call, emphasizing a shift from portfolio transformation to internal execution and growth. The tone was decisive regarding the company's strategic direction and financial targets, with executives speaking candidly about market stabilization and the specific drivers of future growth. There was a notable lack of defensiveness; instead, they focused on the 'momentum' carrying into 2026 and the rigor of their new business systems.
Confidence: HIGH - Management provided specific, data-backed guidance and articulated clear strategic pillars (growth, business system, capital allocation). They directly addressed macro headwinds with specific mitigation strategies (e.g., productivity, mix) and offered granular details on order trends and regional performance, suggesting strong command of the business.
Approximately 3% year over year
Expansion of 60 to 80 basis points
$2.25 to $2.30 per share
Greater than 90%
$0.48 per share
Approximately 2%
Hedging & Uncertainty: Management generally used direct language regarding past performance and specific guidance ranges ('We finished the year strong,' 'guidance is in line'). However, they employed temporal hedging when discussing the realization of operational benefits, using phrases like 'benefits of that, I would say, are to come' and 'we'll continue to drive that as we move through.' They also used probabilistic hedging regarding macro factors, stating 'We expect that to be relatively flat' regarding inflation, and 'We would expect to slightly outperform that' regarding auto builds. This suggests confidence in internal control but appropriate caution regarding external variables.
We finished the year strong, delivering full year organic sales growth of 2%, operating EBITDA growth of 6%, and 100 basis points of margin expansion. - Lori Koch, Chief Executive Officer
Our strategic priorities for 2026 are clear: drive above-market organic growth, continue to build out a robust business system, deploy a balanced capital allocation model. - Lori Koch, Chief Executive Officer
We exceeded our financial guidance on better-than-expected top-line mix and productivity. - Antonella Franzen, Chief Financial Officer
We are off to a good start to the year... we are seeing improving order trends in our industrial technologies business. - Lori Koch, Chief Executive Officer
We're not really expecting any significant headwinds from... logistics, and kind of utilities going into next year. - Lori Koch, Chief Executive Officer
We'll continue to be shareholder-friendly with the deployment of the proceeds. - Lori Koch, Chief Executive Officer
Analyst Sentiment: Analysts were generally constructive, noting the 'solid, clean quarter' and expressing relief that the portfolio transformation noise is in the past. Questions focused heavily on the sustainability of the industrial recovery, the cadence of construction demand, and the mechanics of the innovation pipeline.
Management Responses: Management responses were detailed and open, providing granular data points such as order book visibility (80% monthly) and specific regional growth rates (e.g., China water starting low single digits). They effectively defended their growth thesis against macro skepticism by pointing to specific secular drivers like EVs and medical procedures.
Industrial market recovery and order trends, specifically regarding aerospace and general industrial production.
The cadence of the construction market recovery in 2026, specifically the mix between residential and non-residential.
The impact and mechanics of the 'Vitality Index' and new product margins.
Capital allocation priorities regarding the Aramis divestiture proceeds and M&A pipeline.
Regional performance, specifically the slowdown in China and its impact on the Water segment.
DuPont is successfully executing a post-spin turnaround strategy that is yielding tangible financial results, evidenced by the 100 bps of margin expansion and double-digit EPS growth in 2025. The company has pivoted to a streamlined portfolio focused on high-growth secular markets like Healthcare and Water, which are driving a 30% vitality index and $2B in new product sales. The 2026 guidance for 11% pro forma EPS growth and continued margin expansion demonstrates confidence in their operational excellence initiatives and ability to navigate a mixed macro environment. With a shareholder-friendly capital allocation policy (buybacks, dividends) and >90% FCF conversion, the stock offers a compelling combination of growth, value realization, and resilience against industrial cyclicality.
Overall auto production is expected to be flat in 2026 with weakness in US and Europe. However, EV builds are expected to 'significantly outpace' overall builds, providing a growth lever for DuPont's advanced mobility portfolio.
After years of decline, the construction market is expected to stabilize in 2026 with flattish demand overall. Non-residential and repair/remodel are expected to show low single-digit growth, offsetting persistent weakness in residential construction.
Reduced industrial production in China is creating a headwind for the Water Technologies segment in the first half of 2026, though a ramp-up is anticipated in the second half.
Surgical procedures are expected to grow mid-single digits, with DuPont's portfolio weighted toward higher-growth areas like cardiovascular procedures, supporting mid-single digit growth for the Healthcare segment.